The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B

KAYA, Muhammed; Sirin, Goktug; Güzelbulut, Fatih; dindar, gokhan; Sezikli, Hayrunnisa; sezikli, mesut; Açıkgöz, Seyyid Bilal; Yeşilyurt, Esra

doi:10.4274/vhd.galenos.2020.2020.0008

The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B

Esra YEŞİLYURT, (Karabük Devlet Hastanesi, İç Hastalıkları Kliniği, Karabük, Türkiye)

Muhammed KAYA, (Hitit Üniversitesi, Çorum Erol Olçok Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Çorum, Türkiye)

Gökhan DİNDAR, (Kocaeli Derince Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, Kocaeli, Türkiye)

Seyyid Bilal AÇIKGÖZ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Romatoloji Anabilim Dalı, Samsun, Türkiye)

Fatih GÜZELBULUT, (İstanbul Haydarpaşa Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, İstanbul, Türkiye)

Hayrunnisa SEZİKLİ, (Hitit Üniversitesi, Çorum Erol Olçok Eğitim ve Araştırma Hastanesi, Biyokimya Kliniği, Çorum, Türkiye)

Göktuğ ŞİRİN, (Kocaeli Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kocaeli, Türkiye)

Mesut SEZİKLİ (Hitit Üniversitesi, Çorum Erol Olçok Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, Çorum, Türkiye)

Viral Hepatitis Journal

1 0

Yıl: 2020 Cilt: 26 Sayı: 2 Sayfa Aralığı: 69 - 73 Metin Dili: İngilizce DOI: 10.4274/vhd.galenos.2020.2020.0008 İndeks Tarihi: 14-11-2020

The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B

Öz:

Objectives: The aim of this study was to evaluate the relationshipbetween clinical, biochemical, serological parameters, fibroscanimaging in terms of fibrosis and quantitative hepatitis B surfaceantigen (qHBsAg) levels in patients with chronic hepatitis B (CHB)infection whose treatment has been switched from LAM to TDF.Materials and Methods: The study included 19 patients withCHB and under the LAM treatment. The gender, age, comorbidity,medications, routine laboratuary, creatinine clearance, bone mineraldensity, transient elastography for stage of liver fibrosis and qHBsAglevel were examined.Results: Ten of 19 patients were female and 9 were male. When theqHBsAg titers of the patients at $6^th$ and $12^th$ months were compared,there was a statistically significant decrease in qHBsAg titers of thepatients after the $12^th$ month. There was a significant decrease inliver fibrosis measurements at the $12^th$ month of treatment change.There was a statistically significant positive correlation betweenqHBsAg titers and fibroscan values at baseline and $12^th$ month Conclusion: In this study, the replacement of LAM with TDF mayprevent the resistance problem, and also the decrease in fibrosisvalues and/or qHBsAg levels may contribute to the prevention ofHCC and cirrhosis have been showed

Anahtar Kelime:

Kronik Hepatit B Hastalarında Switch Tedavisinin Karaciğer Fibrozu ve qHBsAg Düzeylerine Etkisi

Öz:

Amaç: Bu çalışmanın amacı, tedavisi LAM’den TDF’ye geçen kronik hepatiti B (KHB) enfeksiyonu olan hastalarda klinik, biyokimyasal, serolojik parametreler, fibroskan görüntüleme ile fibrozis ve kantitatif hepatit B yüzey antijeni (qHBsAg) düzeyleri arasındaki ilişkiyi değerlendirmektir. Gereç ve Yöntemler: Çalışmaya LAM tedavisi altındak 19 KHB hastası dahil edildi. Cinsiyet, yaş, yandaş hastalıkları, ilaçlar, rutin laboratuvar tetkikleri, kreatinin klirensi, kemik mineral dansitesi, fibrozis derecelendirmesi için transient elastografi ölçümü ve qHBsAg seviyeleri belirlendi. Bulgular: 19 hastanın 10’u kadın 9’u erkekti. Hastaların 6. ve 12. ayındaki qHbsaq titreleri değerlendirildiğinde, 12. ayın sonunda qHBsAg titrelerin anlamlı ölçüde düşüş saptandı. Karaciğer fibrozis ölçümlerinde de tedavi değişikliğinin 12. ayında anlamlı düşüş saptandı. Başlangıçtaki ve 12. aydaki qHBsAg titreleri ile fibroscan ölçümleri arasında istatistiki olarak anlamlı bir pozitif korelasyon saptandı. Sonuç: Bu çalışmada LAM yerine TDF’ye geçilmesi ile direnç probleminin çözülebileceği, aynı zamanda qHBsAg titrelerinde ve fibrozis değerlerinde düşüş sağlanarak HCC ve sirozdan da korunulabileceği gösterilmeye çalışılmıştır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Terrault NA, Lok ASF, McMahon BJ, Chang KMi, Hwang JP, Jonas MM, Brown Jr RS, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Corrections to AASLD guidelines on chronic hepatitis B. Hepatology. 2018;67:1560-1599.
2. Rodriguez M, Pascasio JM, Fraga E, Fuentes J, Priento M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Miguel Ángel Casado MÁ, Jorquera F, TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B:TENOSIMP-B study. World J Gastroenterol. 2017;23:7459-7469.
3. Lai C, Chien R, Leung N, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl Med. 1998;339:61-68.
4. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Longterm follow-up of patients with anti-HBe/ HBV DNApositive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000;32:300-306.
5. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatolgy. 2000;32:847-851.
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Fraser Gray D, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
7. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207-210.
8. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N, Lamivudine North American Transplant Group et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001;33:424-432.
9. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007;132:1574-1585.
10. Van Bömmel E, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology. 2002;36:507-508.
11. van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44:318- 325.
12. Marcellin P, Heathcote E.J, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Ovung Kurdas O, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Eng J Med. 2008;359:2442-2455.
13. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
14. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxì A, Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883-891.
15. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A-one year trial of lamivudine for chronic hepatitis. N Engl J Med. 1998;339:61-68.
16. Fasano M, Lampertico P, Marzano A, Marco VD, Niro GA, Brancaccio G, Marengo A, Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol. 2012;56:1254-1258.
17. Hadziyannis SJ, Sevastianos V, Rapti I, Vassşlopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop longterm treatment with adefovir. Gastroenterology. 2012;143:629-36.
18. Köksal İ. Kronik hepatit B’de genel tedavi yaklaşımı. In: Tabak F, Tosun S, eds. Viral Hepatit 2013. Ankara: Viral Hepatitle Savaşım Derneği; 2013:257-264.
19. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Mani Subramanian G, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-475.
20. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojung J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960-974.
21. Chon YE, Choi EH, Song KJ, Park JY, Kim DY, Han KH, Chon CY, Ahn SH, Up Kim S. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a metaanalysis. Plos one. 2012;7:e44930.
22. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis inchronic liver disease: a metaanalysis of diagnostic accuracy. J Hepatol. 2011;54:650-659.
23. Ferraioli G, Tinelli C, Bello BD, Zicchetti M, Lissandrin R, Gaetano Filice G, Filice C, Above E, Barbarini G, Brunetti E, Calderon W, Di Gregorio M, Gulminetti R, Lanzarini P, Ludovisi S, Maiocchi L, Malfitano A, Michelone G, Minoli L, Mondelli M, Novati S, Patruno SFA, Perretti A, Poma G, Sacchi P, Zanaboni D, Zaramella M. Performance of liver stiffness measurements by transient elastography in chronic hepatitis. Wold J Gastroenterol. 2013;19:49-56.
24. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, Dandri M, Petersen J. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007;133:843-852.
25. Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut. 2018;67:2045-2053.
26. Tan Z, Li M, Kuang X, Tang Y, Fan Y, Deng G, Wang Y, He D. Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection. J Clin Virol. 2014;59:228-34.
27. Sali S, Sharafi H, Alavian SH, Alavian SM, Etesam F, Salimi S, Merza MA, Keshvari M. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state? Diagn Microbiol Infect Dis. 2015;82:114-119.
28. Martinot-Peignoux M, Lapalus M, Laouénan C, Lada O, NetooCardoso AC, Boyer N, Ripault MP, Carvalho-Filho R, Asselah T, Marcellin M. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol. 2013;58:401-407.
29. Invernizzi F, Viganò M, Grossi G, Lampertico P The prognosis and management of inactive HBV carriers. Liver Int. 2016;36 (Suppl 1):100-104.

APA	Yeşilyurt E, KAYA M, dindar g, Açıkgöz S, Güzelbulut F, Sezikli H, Sirin G, sezikli m (2020). The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. , 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
Chicago	Yeşilyurt Esra,KAYA Muhammed,dindar gokhan,Açıkgöz Seyyid Bilal,Güzelbulut Fatih,Sezikli Hayrunnisa,Sirin Goktug,sezikli mesut The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. (2020): 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
MLA	Yeşilyurt Esra,KAYA Muhammed,dindar gokhan,Açıkgöz Seyyid Bilal,Güzelbulut Fatih,Sezikli Hayrunnisa,Sirin Goktug,sezikli mesut The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. , 2020, ss.69 - 73. 10.4274/vhd.galenos.2020.2020.0008
AMA	Yeşilyurt E,KAYA M,dindar g,Açıkgöz S,Güzelbulut F,Sezikli H,Sirin G,sezikli m The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. . 2020; 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
Vancouver	Yeşilyurt E,KAYA M,dindar g,Açıkgöz S,Güzelbulut F,Sezikli H,Sirin G,sezikli m The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. . 2020; 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
IEEE	Yeşilyurt E,KAYA M,dindar g,Açıkgöz S,Güzelbulut F,Sezikli H,Sirin G,sezikli m "The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B." , ss.69 - 73, 2020. 10.4274/vhd.galenos.2020.2020.0008
ISNAD	Yeşilyurt, Esra vd. "The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B". (2020), 69-73. https://doi.org/10.4274/vhd.galenos.2020.2020.0008

APA	Yeşilyurt E, KAYA M, dindar g, Açıkgöz S, Güzelbulut F, Sezikli H, Sirin G, sezikli m (2020). The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. Viral Hepatitis Journal, 26(2), 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
Chicago	Yeşilyurt Esra,KAYA Muhammed,dindar gokhan,Açıkgöz Seyyid Bilal,Güzelbulut Fatih,Sezikli Hayrunnisa,Sirin Goktug,sezikli mesut The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. Viral Hepatitis Journal 26, no.2 (2020): 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
MLA	Yeşilyurt Esra,KAYA Muhammed,dindar gokhan,Açıkgöz Seyyid Bilal,Güzelbulut Fatih,Sezikli Hayrunnisa,Sirin Goktug,sezikli mesut The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. Viral Hepatitis Journal, vol.26, no.2, 2020, ss.69 - 73. 10.4274/vhd.galenos.2020.2020.0008
AMA	Yeşilyurt E,KAYA M,dindar g,Açıkgöz S,Güzelbulut F,Sezikli H,Sirin G,sezikli m The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. Viral Hepatitis Journal. 2020; 26(2): 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
Vancouver	Yeşilyurt E,KAYA M,dindar g,Açıkgöz S,Güzelbulut F,Sezikli H,Sirin G,sezikli m The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B. Viral Hepatitis Journal. 2020; 26(2): 69 - 73. 10.4274/vhd.galenos.2020.2020.0008
IEEE	Yeşilyurt E,KAYA M,dindar g,Açıkgöz S,Güzelbulut F,Sezikli H,Sirin G,sezikli m "The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B." Viral Hepatitis Journal, 26, ss.69 - 73, 2020. 10.4274/vhd.galenos.2020.2020.0008
ISNAD	Yeşilyurt, Esra vd. "The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B". Viral Hepatitis Journal 26/2 (2020), 69-73. https://doi.org/10.4274/vhd.galenos.2020.2020.0008